CDK4 and breast cancer: Recently, vepdegestrant, a type of PROTAC ER degrader, has been reported to have potent antitumour efficacy and manageable toxicity in patients with locally advanced or metastatic ER+/HER2− BC who have progressed to CDK4/6i‐based therapy [105].